Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PCVX Vaxcyte, Inc.

交易中 11-13 11:59:20 EST

63.33

-1.36

-2.10%

最高64.64	最低63.00	成交量15.04万
今开64.64	昨收64.69	日振幅2.54%
总市值100.25亿	流通市值92.46亿	总股本1.58亿
成交额953.96万	换手率0.10%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PCVX","market":"US","secType":"STK","nameCN":"Vaxcyte, Inc.","latestPrice":63.33,"timestamp":1794589155199,"preClose":64.69,"halted":0,"volume":150427,"delay":0,"changeRate":-0.021023342093059196,"floatShares":146000000,"shares":158299981,"eps":-8.067474,"marketStatus":"交易中","change":-1.36,"latestTime":"11-13 11:59:20 EST","open":64.64,"high":64.64,"low":63,"amount":9539582.42663,"amplitude":0.025352,"askPrice":63.43,"askSize":200,"bidPrice":63.32,"bidSize":260,"shortable":3,"etf":0,"ttmEps":-8.067474,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794603600000},"marketStatusCode":2,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":64.69,"preHourTrading":{"tag":"盘前","latestPrice":65.71,"preClose":64.69,"latestTime":"09:27 EST","volume":1394,"amount":91032.04744000001,"timestamp":1794580070082,"change":1.02,"changeRate":0.015768,"amplitude":0.048145},"postHourTrading":{"tag":"盘后","latestPrice":64.69,"preClose":64.69,"latestTime":"19:30 EST","volume":18633,"amount":1205448.58,"timestamp":1794529802647,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2771,"impliedVol":0.5162,"impliedVolPercentile":0.4303},"requestUrl":"/m/hq/s/PCVX","defaultTab":"news","newsList":[{"id":"1195953403","title":"异动解读｜Vaxcyte盘中下跌4.21%，缺乏新增消息催化后回吐前期涨幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1195953403","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195953403?lang=zh_cn&edition=full","pubTime":"2026-11-12 23:12","pubTimestamp":1794496348,"startTime":"0","endTime":"0","summary":"11月12日，Vaxcyte盘中下跌4.21%，报65.51美元/股，成交额339.11万美元。近期可见的公开消息主要集中在上月临床与评级进展。公司此前披露，肺炎球菌疫苗VAX-31关键III期试验达到所有预设主要终点，且Needham随后将目标价上调至122美元并维持买入评级；最新季度EPS为每股亏损1.99美元，好于市场预期的每股亏损2.12美元。不过，上述利好均非当日新发布信息，对本次盘中回落的即时解释力有限。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte盘中下跌，缺乏新催化回吐涨幅","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132846070","title":"异动解读｜Vaxcyte盘中下跌5.02%，财报虽优于预期但亏损同比扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1132846070","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132846070?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:43","pubTimestamp":1793900601,"startTime":"0","endTime":"0","summary":"11月6日，Vaxcyte盘中下跌5.02%，报62.48美元/股，成交额3288.0万美元。消息面上，公司最新披露季度每股亏损为1.99美元，好于市场预期的2.12美元，但较上年同期1.56美元亏损水平进一步扩大27.56%，业绩公布后股价承压。Vaxcyte, Inc.于2013年11月27日在特拉华州注册成立。他们的无细胞蛋白质合成平台使他们能够设计和生产蛋白质载体和抗原，这是疫苗的关键组成部分。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报亏损扩大，股价承压走低","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127400058","title":"异动解读｜Vaxcyte, Inc.盘中上涨5.04%，肺炎球菌疫苗利好后获机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1127400058","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127400058?lang=zh_cn&edition=full","pubTime":"2026-10-20 23:09","pubTimestamp":1792508947,"startTime":"0","endTime":"0","summary":"10月20日，Vaxcyte, Inc.盘中上涨5.04%，报66.89美元，成交额4397.09万美元。本次异动可追溯的公开消息面，是公司在成人关键性III期OPUS-1试验中宣布VAX-31达到全部预设主要终点后，获Needham将目标价上调至122美元，并维持买入评级。此前公司披露，VAX-31在不同年龄组中，相较Prevnar 20和或Capvaxive达到全部预设主要终点，且安全性与耐受性表现良好；公司预计其余两项成人III期试验结果将于上半年公布，并支持后续向FDA提交BLA申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vaxcyte盘中上涨，肺炎球菌疫苗利好获机构上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162544816","title":"异动解读｜Vaxcyte, Inc.盘中下跌5.08%，肺炎球菌疫苗利好兑现后股价回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1162544816","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162544816?lang=zh_cn&edition=full","pubTime":"2026-10-14 03:21","pubTimestamp":1791919263,"startTime":"0","endTime":"0","summary":"10月14日，Vaxcyte, Inc.盘中下跌5.08%，报67.05美元/股，成交额8833.69万美元。近期可追溯的明确催化来自公司肺炎球菌结合疫苗VAX-31关键III期OPUS-1试验取得积极顶线结果，且随后有机构将目标价由110美元上调至122美元并维持买入评级。已披露信息显示，VAX-31在III期试验中达到所有预设主要终点，覆盖各年龄组，安全性和耐受性表现良好。此前该结果曾推动股价单日大幅上行，本次盘中下跌5.08%更多体现利好后的阶段性回吐。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"肺炎球菌疫苗利好兑现，Vaxcyte股价回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146887167","title":"异动解读｜Vaxcyte盘中上涨5.24%，肺炎疫苗三期数据推动股价波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1146887167","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146887167?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:17","pubTimestamp":1791555421,"startTime":"0","endTime":"0","summary":"10月9日，Vaxcyte盘中上涨5.24%，报68.415美元，成交额2495万美元。此前该公司31价肺炎球菌疫苗VAX-31在三期试验中达所有主要终点，股价大幅走高后出现剧烈波动。Needham将目标价从110美元上调至122美元，维持买入评级。Vaxcyte是一家下一代疫苗创新企业，通过无细胞蛋白质合成平台开发预防致命传染病的疫苗，其31价肺炎球菌疫苗VAX-31预计2028年上半年提交FDA生物制品许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"肺炎疫苗三期数据亮眼，Vaxcyte盘中上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105136737","title":"异动解读｜Vaxcyte盘中下跌5.92%，增发融资引发股权稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1105136737","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105136737?lang=zh_cn&edition=full","pubTime":"2026-10-06 21:33","pubTimestamp":1791293620,"startTime":"0","endTime":"0","summary":"10月6日，Vaxcyte盘中下跌5.92%，报67.455美元，成交额2477.41万美元。公司在肺炎疫苗三期试验成功刺激股价大涨后，宣布启动普通股、预先融资认股权证及可转换优先票据的公开发行计划，引发市场对股权稀释的担忧，形成短期获利回吐压力。该公司是一家下一代疫苗创新企业，通过无细胞蛋白质合成平台开发预防致命传染病的疫苗，其31价肺炎球菌疫苗VAX-31预计2028年上半年提交FDA生物制品许可申请。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte下跌，增发引发稀释担忧","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137757433","title":"异动解读｜Vaxcyte盘后下跌5.39%，拟增发新股及可转债融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1137757433","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137757433?lang=zh_cn&edition=full","pubTime":"2026-10-06 05:34","pubTimestamp":1791236079,"startTime":"0","endTime":"0","summary":"10月6日，Vaxcyte盘后下跌5.39%，报69.69美元。消息面上，公司在肺炎疫苗三期试验成功刺激股价大涨逾50%后，宣布启动普通股、预先融资认股权证及可转换优先票据的公开发行计划。此举引发市场对股权稀释的担忧，形成短期获利回吐压力。该公司是一家下一代疫苗创新企业，通过无细胞蛋白质合成平台开发预防致命传染病的疫苗，其31价肺炎球菌疫苗VAX-31预计2028年上半年提交FDA生物制品许可申请。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte拟增发融资，盘后承压下跌","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147381016","title":"异动解读｜Vaxcyte盘中上涨53.91%，肺炎疫苗三期数据报捷","url":"https://stock-news.laohu8.com/highlight/detail?id=1147381016","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147381016?lang=zh_cn&edition=full","pubTime":"2026-10-05 21:44","pubTimestamp":1791207883,"startTime":"0","endTime":"0","summary":"10月5日，Vaxcyte盘中上涨53.91%，报87.055美元。消息面上公司31价肺炎球菌疫苗VAX-31在关键性Ⅲ期OPUS-1试验中达所有主要终点，数据显示其免疫原性优于对照组Prevnar 20和Capvaxive。试验结果将作为该公司2028年上半年向FDA提交生物制品许可申请的核心数据，另两项成人Ⅲ期试验预计2027年上半年完成。公司简介：Vaxcyte是一家下一代疫苗公司，致力于通过开发新型疫苗预防全球常见致命传染病改善全球健康。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673108884","title":"美股开盘涨跌不一，Vaxcyte 大涨 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673108884","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673108884?lang=zh_cn&edition=full","pubTime":"2026-10-05 21:31","pubTimestamp":1791207107,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，美股开盘，道指跌 0.1%，标普 500 指数涨 0.07%，纳指涨 0.1%。明星科技股涨跌不一，英特尔跌 2.8%，台积电涨 1.1%，英伟达涨 0.6%。Vaxcyte 大涨 53%，公司肺炎球菌疫苗达到后期临床试验目标。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2294225","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","IE0009354923.USD","PCVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043187","title":"Vaxcyte（PCVX）涨超70% 公布VAX-31关键III期阳性数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043187","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673043187?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:42","pubTimestamp":1791196940,"startTime":"0","endTime":"0","summary":"金吾财讯 | Vaxcyte（PCVX）盘前股价扬升，最新涨78.27%，报99美元。消息面上，临床阶段疫苗企业Vaxcyte公布成人关键性III期OPUS-1试验积极顶线数据。本次试验评估下一代31价肺炎球菌结合疫苗候选产品VAX-31的安全性、耐受性与免疫原性，用于预防侵袭性肺炎球菌病及肺炎球菌性肺炎。OPUS-1的试验数据，将作为公司向美国FDA提交生物制品许可申请（BLA）的核心支撑材料。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","IE0009354923.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673010637","title":"美股Vaxcyte股价盘前涨超73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673010637","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673010637?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:41","pubTimestamp":1791196889,"startTime":"0","endTime":"0","summary":"美股Vaxcyte股价盘前涨超73%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202610053888658422.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202610053888658422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0053671581.USD","IE0009354923.USD","PCVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673016947","title":"Vaxcyte美股盘前大涨超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673016947","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673016947?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:36","pubTimestamp":1791196617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PCVX","BK4139","LU0053671581.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070183","title":"Vaxcyte股价盘前大涨超61%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673070183?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:26","pubTimestamp":1791195997,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PCVX","LU0053671581.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129202719","title":"Vaxcyte宣布肺炎球菌疫苗达到后期临床试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1129202719","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129202719?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:16","pubTimestamp":1791195393,"startTime":"0","endTime":"0","summary":"10月5日，Vaxcyte盘前飙涨逾37%，此前该公司的肺炎球菌疫苗达到后期临床试验目标。","market":"us","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vaxcyte宣布肺炎球菌疫苗达到后期临床试验目标","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673462709","title":"美股Vaxcyte股价盘前大涨25.6%，此前该公司的肺炎球菌疫苗达到后期临床试验目标。","url":"https://stock-news.laohu8.com/highlight/detail?id=2673462709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673462709?lang=zh_cn&edition=full","pubTime":"2026-10-05 18:11","pubTimestamp":1791195107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","PCVX","IBBJ","MDTX","LU0053671581.USD","PSYK","IE0009354923.USD","IBBQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142006324","title":"Vaxcyte任命首席医疗官及首席法务官，并收窄Vax-31 Opus-1关键数据发布预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1142006324","media":"美股速递","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142006324?lang=zh_cn&edition=full","pubTime":"2026-09-04 04:06","pubTimestamp":1788465978,"startTime":"0","endTime":"0","summary":"Vaxcyte宣布了两项重要人事任命，同时进一步明确了其核心候选疫苗Vax-31的Opus-1临床研究关键数据发布的时间窗口。在领导层补强的同时，Vaxcyte也对其Vax-31 Opus-1研究的顶线数据揭晓预期进行了收窄，给出了更为具体的时间指引。市场分析人士认为，Vaxcyte此番人事布局与预期管理并行，旨在为其核心资产的潜在商业化与监管互动铺平道路。随着Vax-31关键数据的临近，公司高层的稳定与决策效率将变得至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009354923.USD","PCVX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155910968","title":"Vaxcyte启动Vax-a1一期临床研究，首位健康成人受试者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1155910968","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155910968?lang=zh_cn&edition=full","pubTime":"2026-06-03 04:06","pubTimestamp":1780430800,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc. 宣布，其旨在预防A组链球菌所致疾病的研究性疫苗Vax-a1，已在一期临床试验中为首位健康成人受试者完成给药。该研究旨在评估Vax-a1在健康成年人群中的安全性、耐受性和免疫原性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4139","PCVX","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517346929","title":"Vaxcyte, Inc.盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517346929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517346929?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:45","pubTimestamp":1741207533,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时45分，Vaxcyte, Inc.股票出现波动，股价快速上涨5.10%。Vaxcyte, Inc.股票所在的生物技术行业中，整体涨幅为1.97%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家疫苗公司，致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者，从而改善全球健康状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306044533a2612eba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306044533a2612eba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","PCVX","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516552206","title":"Vaxcyte, Inc.2024财年实现净利润-4.64亿美元，同比减少15.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516552206?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844868,"startTime":"0","endTime":"0","summary":"3月2日，Vaxcyte, Inc.公布财报，公告显示公司2024财年净利润为-4.64亿美元，同比减少15.42%；其中营业收入为0.00美元，每股基本收益为-3.80美元。从资产负债表来看，Vaxcyte, Inc.总负债2.27亿美元，其中短期债务5.89百万美元，资产负债比为15.57，流动比率为12.78。机构评级：截至2025年3月2日，当前有9家机构对Vaxcyte, Inc.目标价做出预测，其中目标均价为150.22美元，其中最低目标价为135.00美元，最高目标价为163.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000148abe2c5d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000148abe2c5d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514333298","title":"Vaxcyte, Inc.盘中异动 下午盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514333298","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514333298?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:07","pubTimestamp":1740686870,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时07分，Vaxcyte, Inc.股票出现波动，股价快速下跌5.08%。Vaxcyte, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1919.08%、338.83%、188.69%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Vaxcyte, Inc.公司简介：Vaxcyte Inc 是一家疫苗公司，致力于通过开发新型疫苗来治疗患有最常见和致命疾病的患者，从而改善全球健康状况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228040750a256c504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228040750a256c504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","BK4139","LU0053671581.USD","PCVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vaxcyte.com","stockEarnings":[{"period":"1week","weight":0.0447},{"period":"1month","weight":-0.0316},{"period":"3month","weight":0.114},{"period":"6month","weight":0.2348},{"period":"1year","weight":0.4033},{"period":"ytd","weight":0.402}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vaxcyte, Inc.于2013年11月27日在特拉华州注册成立。该公司是一家下一代疫苗公司，旨在通过开发预防或治疗全球某些最常见和致命的传染病的新型疫苗来改善全球健康状况。他们的无细胞蛋白质合成平台使他们能够设计和生产蛋白质载体和抗原，这是疫苗的关键组成部分。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.007757},{"month":2,"riseRate":0.5,"avgChangeRate":0.015611},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.13682},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.015657},{"month":5,"riseRate":0.5,"avgChangeRate":0.041128},{"month":6,"riseRate":0.833333,"avgChangeRate":0.031665},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.000114},{"month":8,"riseRate":0.857143,"avgChangeRate":0.131285},{"month":9,"riseRate":0.428571,"avgChangeRate":0.06838},{"month":10,"riseRate":0.428571,"avgChangeRate":0.102521},{"month":11,"riseRate":0.571429,"avgChangeRate":-0.016003},{"month":12,"riseRate":0.5,"avgChangeRate":0.007817}],"exchange":"NASDAQ","name":"Vaxcyte, Inc.","nameEN":"Vaxcyte, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Vaxcyte, Inc.(PCVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Vaxcyte, Inc.,PCVX,Vaxcyte, Inc.股票,Vaxcyte, Inc.股票老虎,Vaxcyte, Inc.股票老虎国际,Vaxcyte, Inc.行情,Vaxcyte, Inc.股票行情,Vaxcyte, Inc.股价,Vaxcyte, Inc.股市,Vaxcyte, Inc.股票价格,Vaxcyte, Inc.股票交易,Vaxcyte, Inc.股票购买,Vaxcyte, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vaxcyte, Inc.(PCVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Vaxcyte, Inc.(PCVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}